At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,525 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for COVID-19. Completed, enrolled 1,525 participants across 96 sites in 13 countries.
Detailed Summary
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesArgentina, Brazil, Germany, India, Italy, Japan, Mexico, Puerto Rico, Russia, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJun 2020
Primary CompletionFeb 2021
Study CompletionJun 2021
TodayJul 2026
First PostedJun 9, 2020
Enrollment StartJun 12, 2020
Primary CompletionFeb 12, 2021
Study CompletionJun 10, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.1 years ago
Interventions
Baricitinibdrug
Given orally
Placebodrug
Given orally